Continued Access to RXDX-105
Sponsored by Memorial Sloan Kettering Cancer Center
About this trial
Last updated a year ago
Study ID
18-487
Status
Completed
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Ended 6 years ago
What is this trial about?
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
What are the participation requirements?
Inclusion Criteria
* This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):
Exclusion Criteria
* Any patients other than those described above are excluded.